Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced an agreement with a leading group purchasing organization (GPO) that will provide coverage for TONMYA (cyclobenzaprine HCl sublingual tablets) to approximately 35 million U.S. commercial lives, representing about 20% of the commercial market. The agreement, effective May 1, 2026, includes standard utilization management criteria and marks a significant milestone in the company’s efforts to broaden patient access to its FDA-approved non-opioid treatment for fibromyalgia.
Fibromyalgia affects an estimated 6 million Americans, yet treatment options have been limited. TONMYA, approved by the FDA in 2024, is the first new therapy for the condition in more than 15 years. The GPO agreement is expected to facilitate coverage for a substantial portion of commercially insured patients, potentially increasing prescription volumes and revenue for Tonix. The company is also pursuing additional coverage across commercial and government channels, with existing Medicaid coverage already in place in 38 states, covering approximately 55 million lives.
The deal underscores the growing demand for non-opioid pain management alternatives amid the ongoing opioid crisis. TONMYA offers a sublingual formulation of cyclobenzaprine, a muscle relaxant, designed for rapid absorption and improved tolerability. Analysts view the GPO agreement as a critical step in establishing TONMYA’s market presence and driving adoption among healthcare providers.
Tonix Pharmaceuticals is a fully integrated commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments. Its CNS portfolio includes marketed products for acute migraine, such as Zembrace SymTouch and Tosymra, and a pipeline targeting major depressive disorder, acute stress disorder, and Prader-Willi syndrome. The company is also advancing immunology programs, including monoclonal antibodies for Lyme disease prophylaxis and kidney transplant rejection prevention.
Investors have responded positively to the news, viewing the GPO agreement as a validation of TONMYA’s commercial potential. For more information, visit the company’s newsroom at https://ibn.fm/TNXP. The full press release is available at https://ibn.fm/ShicX.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Tonix Pharmaceuticals Secures GPO Agreement Covering 35 Million Lives for TONMYA, Expanding Access to Non-Opioid Fibromyalgia Treatment.